DNA修復薬の世界市場レポート 2025年

DNA修復薬市場規模は、今後数年間で飛躍的な成長が見込まれます。2029年にはCAGR20.0％で272億2,000万米ドルに成長します。予測期間の成長は、DNA修復のための標的療法の開発、精密医療への関心の高まり、高齢化人口の増加、DNA修復薬開発のための資金増加などに起因すると考えられます。予測期間の主な動向には、DNA修復の創薬における人工知能の統合、DNA修復経路を標的とした併用療法の開発、遺伝子編集技術の重視、DNA修復プロファイルに基づく個別化治療レジメン、DNA修復薬の臨床試験の増加などが含まれます。

がんの有病率の増加は、DNA修復薬市場の今後の成長を牽引すると予想されます。がんは、異常な細胞が制御不能に増殖し、典型的な境界を越えて他の臓器に転移したり、近隣の組織に侵入する可能性がある場合に、ほとんどすべての臓器や組織で開発される可能性があります。このようながん患者の増加は、主に喫煙、放射線被曝、発がん性物質、肥満、遺伝子変異などの要因によるものです。DNAの自己修復能力を阻害することで、これらの薬剤はがん細胞の複製を停止させ、最終的には死滅させることができます。例えば、オーストラリア保健福祉研究所の報告によると、オーストラリアにおけるがんの診断数は、2022年の160,570人から2023年には164,694人に増加し、毎年大幅に増加しています。この動向は、同国におけるがんの有病率の増加を浮き彫りにしており、DNA修復薬市場の拡大に拍車をかけています。

個別化医療に対する需要の高まりが、今後のDNA修復薬市場の拡大を牽引すると予想されます。個別化医療とは、患者の遺伝子、環境、ライフスタイルの個人差を考慮したヘルスケアへの革新的なアプローチです。DNA修復薬は、患者のユニークな遺伝子プロファイルに合わせた治療を可能にするため、この分野で不可欠です。これらの医薬品は、がん治療、バイオマーカーの同定、副作用の最小化など、個別化医療に応用されています。例えば、個別化医療連合（Personalized Medicine Coalition）の報告によると、2022年に新たに承認された治療薬のうち、12の個別化治療薬が占める割合は約34％で、以前に比べて大幅に増加しています。このように、個別化医療に対する需要の高まりが、DNA修復薬市場の今後の成長に拍車をかけています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界DNA修復薬PESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界のDNA修復薬市場：成長率分析
• 世界のDNA修復薬市場の実績：規模と成長, 2019-2024
• 世界のDNA修復薬市場の予測：規模と成長, 2024-2029, 2034F
• 世界DNA修復薬総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界のDNA修復薬市場薬の種類別、実績と予測, 2019-2024, 2024-2029F, 2034F
• オラパリブ
• ルカパリブ
• ニラパリブ
• タラゾパリブ
• その他の薬物
• 世界のDNA修復薬市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院薬局
• 小売薬局
• その他の流通チャネル
• 世界のDNA修復薬市場：用途別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 卵巣がん
• 卵管がん
• 腹膜がん
• 乳がん
• その他の用途
• 世界のDNA修復薬市場、オラパリブのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• タブレット
• カプセル
• 併用療法
• 世界のDNA修復薬市場、ルカパリブのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• タブレット
• 単独療法
• 他のがん治療との併用
• 世界のDNA修復薬市場ニラパリブのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• カプセル
• 徐放性製剤
• 維持療法アプリケーション
• 世界のDNA修復薬市場、タラゾパリブのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• カプセル
• 免疫療法との併用
• 高用量と低用量のオプション
• 世界のDNA修復薬市場、その他の医薬品のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 実験的PARP阻害剤
• ジェネリック医薬品とバイオシミラー医薬品
• 次世代DNA損傷応答（DDR）阻害剤

第7章 地域別・国別分析

• 世界のDNA修復薬市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界のDNA修復薬市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• DNA修復薬市場：競合情勢
• DNA修復薬市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Johnson & Johnson Private Limited Overview, Products and Services, Strategy and Financial Analysis
  • AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • Novartis AG Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Bristol-Myers Squibb Company
• AstraZeneca PLC
• Sanofi S.A.
• GlaxoSmithKline plc.
• Takeda Pharmaceutical Company Limited
• Gilead Sciences Inc.
• Amgen Inc.
• Merck KGaA
• Regeneron Pharmaceuticals Inc.
• Biogen Inc.
• Ono Pharmaceutical Co. Ltd.
• Jiangsu HengRui Medicine Co. Ltd.
• BioMarin Pharmaceutical Inc.
• Genentech Inc.
• ClovisOncology Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• DNA修復薬市場2029：新たな機会を提供する国
• DNA修復薬市場2029：新たな機会を提供するセグメント
• DNA修復薬市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

DNA repair drugs are therapeutic agents aimed at enhancing or restoring the body's natural mechanisms for repairing damaged DNA in cells. These medications are utilized to treat a variety of conditions, including cancer, by encouraging the repair of genetic mutations and boosting the efficacy of other treatments such as chemotherapy and radiation.

The primary types of DNA repair drugs include olaparib, rucaparib, niraparib, talazoparib, and others. Olaparib, for instance, is a medication prescribed for adults dealing with specific forms of prostate cancer, pancreatic cancer, breast cancer, ovarian cancer, fallopian tube cancer, or primary peritoneal cancer, either as a standalone treatment or in combination with other medications. These drugs are made available through hospital pharmacies, retail pharmacies, and other distribution channels for the treatment of conditions such as ovarian cancer, fallopian tube cancer, peritoneal cancer, breast cancer, and more.

The DNA repair drugs research report is one of a series of new reports from The Business Research Company that provides DNA repair drugs market statistics, including the DNA repair drugs industry's global market size, regional shares, competitors with DNA repair drugs market share, detailed DNA repair drugs market segments, market trends and opportunities, and any further data you may need to thrive in the DNA repair drugs industry. This DNA repair drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The DNA repair drugs market size has grown exponentially in recent years. It will grow from $10.78 billion in 2024 to $13.11 billion in 2025 at a compound annual growth rate (CAGR) of 21.6%. The growth in the historic period can be attributed to increasing understanding of DNA repair mechanisms, growth in cancer research, evolving regulatory landscape for pharmaceuticals, rising prevalence of genetic disorders, expansion of personalized medicine

The DNA repair drugs market size is expected to see exponential growth in the next few years. It will grow to $27.22 billion in 2029 at a compound annual growth rate (CAGR) of 20.0%. The growth in the forecast period can be attributed to development of targeted therapies for DNA repair, growing focus on precision medicine, rise in the aging population, increased funding for DNA repair drug development. Major trends in the forecast period include integration of artificial intelligence in drug discovery for DNA repair, development of combination therapies targeting DNA repair pathways, emphasis on gene editing technologies, personalized treatment regimens based on DNA repair profiles, rise in clinical trials for DNA repair drugs.

The increasing prevalence of cancer is anticipated to drive the growth of the DNA repair drug market in the future. Cancer can develop in almost any organ or tissue when abnormal cells grow uncontrollably, exceeding their typical boundaries and potentially spreading to other organs or invading nearby tissues. This rise in cancer cases is primarily attributed to factors such as smoking, radiation exposure, carcinogenic substances, obesity, and genetic mutations. By hindering DNA's self-repair capabilities, these drugs can cause cancerous cells to cease replication and eventually die. For example, the Australian Institute of Health and Welfare reported that the number of cancer diagnoses in Australia rose from 160,570 in 2022 to 164,694 in 2023, indicating a significant annual increase. This trend underscores the growing prevalence of cancer in the country, which in turn is fueling the expansion of the DNA repair drug market.

The growing demand for personalized medicine is expected to drive the expansion of the DNA repair drug market in the future. Personalized medicine is an innovative approach to healthcare that considers individual differences in patients' genes, environments, and lifestyles. DNA repair drugs are vital in this field, as they allow treatments to be tailored to the unique genetic profiles of patients. These drugs are used in personalized medicine for cancer treatment, biomarker identification, and minimizing adverse effects, among other applications. For example, the Personalized Medicine Coalition reported that in 2022, the approval of 12 new personalized medicines accounted for about 34% of all newly approved therapies, marking a significant increase compared to previous years. Thus, the rising demand for personalized medicine is fueling the growth of the DNA repair drug market moving forward.

DNA repair drug market is witnessing a prominent trend of product innovation. Leading companies in the DNA repair drugs sector are actively engaged in developing groundbreaking products to fortify their market presence. A notable example is AstraZeneca PLC, a UK-based biopharmaceutical company, which secured approval in June 2023 for Lynparza plus abiraterone in the United States. This approval is specifically for treating BRCA-mutated metastatic castration-resistant prostate cancer. Lynparza (olaparib), the first-of-its-kind PARP inhibitor, represents a breakthrough as the initial targeted drug capable of blocking the DNA damage response (DDR) in cells or tumors without homologous recombination repair (HRR).

Major players in the DNA repair drug market are directing their efforts toward the development of innovative solutions, such as oral poly ADP-ribose polymerase (PARP) inhibitors. These medications, administered orally, are designed to target the PARP enzyme's activity. Pfizer Inc., a prominent US-based pharmaceutical company, exemplifies this trend with the FDA approval announcement in June 2023 for 'TALZENNA' (talazoparib). TALZENNA, the first and only PARP inhibitor approved for use alongside the established standard of care, XTANDI, is intended for adult patients diagnosed with metastatic castration-resistant prostate cancer (mCRPC) exhibiting mutations in homologous recombination repair (HRR) genes. By inhibiting PARP enzyme activity and capturing PARP at the DNA damage site, TALZENNA hinders cancer cell growth and induces cell death.

In November 2022, Alexion Pharmaceuticals Inc., a US-based biopharmaceutical company specializing in rare disorder therapies, acquired LogicBio Therapeutics Inc. for an undisclosed sum. This acquisition positions Alexion to expedite its foray into genomic therapeutics, leveraging LogicBio's distinctive technology, seasoned rare disease R&D team, and expertise in pre-clinical development. LogicBio Therapeutics Inc. is a clinical-stage genetic medicine company with a focus on gene delivery and gene editing platforms to address rare diseases.

Major companies operating in the DNA repair drugs market include Pfizer Inc., Johnson & Johnson Private Limited, AbbVie Inc., Bayer AG, Novartis AG, Bristol-Myers Squibb Company, AstraZeneca PLC, Sanofi S.A., GlaxoSmithKline plc., Takeda Pharmaceutical Company Limited, Gilead Sciences Inc., Amgen Inc., Merck KGaA, Regeneron Pharmaceuticals Inc., Biogen Inc., Ono Pharmaceutical Co. Ltd., Jiangsu HengRui Medicine Co. Ltd., BioMarin Pharmaceutical Inc., Genentech Inc., ClovisOncology Inc., Karyopharm Therapeutics Inc., Repare Therapeutics Inc., Intellia Therapeutics Inc., C4 Therapeutics Inc., Precision BioSciences, Artios Pharma Limited, FoRx Therapeutics AG, Onxeo SA, CRISPR Therapeutics AG

North America was the largest region in the DNA repair drugs market in 2024, and is expected to be the fastest-growing region in the forecast period. The regions covered in the dna repair drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the dna repair drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The DNA repair drugs market consists of sales of veliparib, methyl methane sulfonate, mitomycin C, and cisplatin. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

DNA Repair Drugs Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on dna repair drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for dna repair drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The dna repair drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Drug Type: Olaparib; Rucaparib; Niraparib; Talazoparib; Other Drugs
• 2) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Other Distribution Channels
• 3) By Application: Ovarian Cancer; Fallopian Tube Cancer; Peritoneal Cancer; Breast Cancer; Other Applications
• Subsegments:
• 1) By Olaparib: Tablets; Capsules; Combination Therapies
• 2) By Rucaparib: Tablets; Monotherapy; Combination with Other Cancer Treatments
• 3) By Niraparib: Capsules; Extended-Release Formulations; Maintenance Therapy Applications
• 4) By Talazoparib: Capsules; Combination with Immunotherapy; High-Dose and Low-Dose Options
• 5) By Other Drugs: Experimental PARP Inhibitors; Generic and Biosimilar Versions; Next-Generation DNA Damage Response (DDR) Inhibitors
• Companies Mentioned: Pfizer Inc.; Johnson & Johnson Private Limited; AbbVie Inc.; Bayer AG; Novartis AG
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. DNA Repair Drugs Market Characteristics

3. DNA Repair Drugs Market Trends And Strategies

4. DNA Repair Drugs Market - Macro Economic Scenario including the impact of Interest Rates, Inflation, Geopolitics and Covid And Recovery on the Market

5. Global DNA Repair Drugs Growth Analysis And Strategic Analysis Framework

• 5.1. Global DNA Repair Drugs PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global DNA Repair Drugs Market Growth Rate Analysis
• 5.4. Global DNA Repair Drugs Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global DNA Repair Drugs Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global DNA Repair Drugs Total Addressable Market (TAM)

6. DNA Repair Drugs Market Segmentation

• 6.1. Global DNA Repair Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Olaparib
• Rucaparib
• Niraparib
• Talazoparib
• Other Drugs
• 6.2. Global DNA Repair Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Retail Pharmacies
• Other Distribution Channels
• 6.3. Global DNA Repair Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Ovarian Cancer
• Fallopian Tube Cancer
• Peritoneal Cancer
• Breast Cancer
• Other Applications
• 6.4. Global DNA Repair Drugs Market, Sub-Segmentation Of Olaparib, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Tablets
• Capsules
• Combination Therapies
• 6.5. Global DNA Repair Drugs Market, Sub-Segmentation Of Rucaparib, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Tablets
• Monotherapy
• Combination with Other Cancer Treatments
• 6.6. Global DNA Repair Drugs Market, Sub-Segmentation Of Niraparib, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Capsules
• Extended-Release Formulations
• Maintenance Therapy Applications
• 6.7. Global DNA Repair Drugs Market, Sub-Segmentation Of Talazoparib, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Capsules
• Combination with Immunotherapy
• High-Dose and Low-Dose Options
• 6.8. Global DNA Repair Drugs Market, Sub-Segmentation Of Other Drugs, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Experimental PARP Inhibitors
• Generic and Biosimilar Versions
• Next-Generation DNA Damage Response (DDR) Inhibitors

7. DNA Repair Drugs Market Regional And Country Analysis

• 7.1. Global DNA Repair Drugs Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global DNA Repair Drugs Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific DNA Repair Drugs Market

• 8.1. Asia-Pacific DNA Repair Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific DNA Repair Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific DNA Repair Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific DNA Repair Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China DNA Repair Drugs Market

• 9.1. China DNA Repair Drugs Market Overview
• 9.2. China DNA Repair Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China DNA Repair Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China DNA Repair Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India DNA Repair Drugs Market

• 10.1. India DNA Repair Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India DNA Repair Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India DNA Repair Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan DNA Repair Drugs Market

• 11.1. Japan DNA Repair Drugs Market Overview
• 11.2. Japan DNA Repair Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan DNA Repair Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan DNA Repair Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia DNA Repair Drugs Market

• 12.1. Australia DNA Repair Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia DNA Repair Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia DNA Repair Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia DNA Repair Drugs Market

• 13.1. Indonesia DNA Repair Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia DNA Repair Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia DNA Repair Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea DNA Repair Drugs Market

• 14.1. South Korea DNA Repair Drugs Market Overview
• 14.2. South Korea DNA Repair Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea DNA Repair Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea DNA Repair Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe DNA Repair Drugs Market

• 15.1. Western Europe DNA Repair Drugs Market Overview
• 15.2. Western Europe DNA Repair Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe DNA Repair Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe DNA Repair Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK DNA Repair Drugs Market

• 16.1. UK DNA Repair Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK DNA Repair Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK DNA Repair Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany DNA Repair Drugs Market

• 17.1. Germany DNA Repair Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany DNA Repair Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany DNA Repair Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France DNA Repair Drugs Market

• 18.1. France DNA Repair Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France DNA Repair Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France DNA Repair Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy DNA Repair Drugs Market

• 19.1. Italy DNA Repair Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy DNA Repair Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy DNA Repair Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain DNA Repair Drugs Market

• 20.1. Spain DNA Repair Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain DNA Repair Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain DNA Repair Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe DNA Repair Drugs Market

• 21.1. Eastern Europe DNA Repair Drugs Market Overview
• 21.2. Eastern Europe DNA Repair Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe DNA Repair Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe DNA Repair Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia DNA Repair Drugs Market

• 22.1. Russia DNA Repair Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia DNA Repair Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia DNA Repair Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America DNA Repair Drugs Market

• 23.1. North America DNA Repair Drugs Market Overview
• 23.2. North America DNA Repair Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America DNA Repair Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America DNA Repair Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA DNA Repair Drugs Market

• 24.1. USA DNA Repair Drugs Market Overview
• 24.2. USA DNA Repair Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA DNA Repair Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA DNA Repair Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada DNA Repair Drugs Market

• 25.1. Canada DNA Repair Drugs Market Overview
• 25.2. Canada DNA Repair Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada DNA Repair Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada DNA Repair Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America DNA Repair Drugs Market

• 26.1. South America DNA Repair Drugs Market Overview
• 26.2. South America DNA Repair Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America DNA Repair Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America DNA Repair Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil DNA Repair Drugs Market

• 27.1. Brazil DNA Repair Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil DNA Repair Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil DNA Repair Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East DNA Repair Drugs Market

• 28.1. Middle East DNA Repair Drugs Market Overview
• 28.2. Middle East DNA Repair Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East DNA Repair Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East DNA Repair Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa DNA Repair Drugs Market

• 29.1. Africa DNA Repair Drugs Market Overview
• 29.2. Africa DNA Repair Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa DNA Repair Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa DNA Repair Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. DNA Repair Drugs Market Competitive Landscape And Company Profiles

• 30.1. DNA Repair Drugs Market Competitive Landscape
• 30.2. DNA Repair Drugs Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Johnson & Johnson Private Limited Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Novartis AG Overview, Products and Services, Strategy and Financial Analysis

31. DNA Repair Drugs Market Other Major And Innovative Companies

• 31.1. Bristol-Myers Squibb Company
• 31.2. AstraZeneca PLC
• 31.3. Sanofi S.A.
• 31.4. GlaxoSmithKline plc.
• 31.5. Takeda Pharmaceutical Company Limited
• 31.6. Gilead Sciences Inc.
• 31.7. Amgen Inc.
• 31.8. Merck KGaA
• 31.9. Regeneron Pharmaceuticals Inc.
• 31.10. Biogen Inc.
• 31.11. Ono Pharmaceutical Co. Ltd.
• 31.12. Jiangsu HengRui Medicine Co. Ltd.
• 31.13. BioMarin Pharmaceutical Inc.
• 31.14. Genentech Inc.
• 31.15. ClovisOncology Inc.

32. Global DNA Repair Drugs Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The DNA Repair Drugs Market

34. Recent Developments In The DNA Repair Drugs Market

35. DNA Repair Drugs Market High Potential Countries, Segments and Strategies

• 35.1 DNA Repair Drugs Market In 2029 - Countries Offering Most New Opportunities
• 35.2 DNA Repair Drugs Market In 2029 - Segments Offering Most New Opportunities
• 35.3 DNA Repair Drugs Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer